Novel Applications of Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Therapeutics

Página do item simplificado
dc.contributor.authorOzaki Tan, Sho Joseph
dc.contributor.authorFloriano, Juliana Ferreria [UNESP]
dc.contributor.authorNicastro, Laura
dc.contributor.authorEmanueli, Costanza
dc.contributor.authorCatapano, Francesco
dc.contributor.institutionImperial Coll London
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2020-12-10T17:36:13Z
dc.date.available2020-12-10T17:36:13Z
dc.date.issued2020-05-01
dc.description.abstractCardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally, representing approximately a third of all deaths every year. The greater part of these cases is represented by myocardial infarction (MI), or heart attack as it is better known, which occurs when declining blood flow to the heart causes injury to cardiac tissue. Mesenchymal stem cells (MSCs) are multipotent stem cells that represent a promising vector for cell therapies that aim to treat MI due to their potent regenerative effects. However, it remains unclear the extent to which MSC-based therapies are able to induce regeneration in the heart and even less clear the degree to which clinical outcomes could be improved. Exosomes, which are small extracellular vesicles (EVs) known to have implications in intracellular communication, derived from MSCs (MSC-Exos), have recently emerged as a novel cell-free vector that is capable of conferring cardio-protection and regeneration in target cardiac cells. In this review, we assess the current state of research of MSC-Exos in the context of MI. In particular, we place emphasis on the mechanisms of action by which MSC-Exos accomplish their therapeutic effects, along with commentary on the current difficulties faced with exosome research and the ongoing clinical applications of stem-cell derived exosomes in different medical contexts.en
dc.description.affiliationImperial Coll London, Natl Heart & Lung Inst, London W12 0NN, England
dc.description.affiliationSao Paulo State Univ, Botucatu Med Sch, BR-18618687 Botucatu, SP, Brazil
dc.description.affiliationUnespSao Paulo State Univ, Botucatu Med Sch, BR-18618687 Botucatu, SP, Brazil
dc.description.sponsorshipBritish Heart Foundation
dc.description.sponsorshipCentre of Vascular Regeneration
dc.description.sponsorshipBSc Medical Biosciences Programme
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipICTEM MRes/PhD Studentship
dc.description.sponsorshipIdBritish Heart Foundation: RG/15/5/31446
dc.description.sponsorshipIdBritish Heart Foundation: CH/15/1/31199
dc.description.sponsorshipIdCentre of Vascular Regeneration: BHF-CVR2
dc.description.sponsorshipIdFAPESP: 2019/02405-4
dc.format.extent30
dc.identifierhttp://dx.doi.org/10.3390/biom10050707
dc.identifier.citationBiomolecules. Basel: Mdpi, v. 10, n. 5, 30 p., 2020.
dc.identifier.doi10.3390/biom10050707
dc.identifier.urihttp://hdl.handle.net/11449/195486
dc.identifier.wosWOS:000545013700044
dc.language.isoeng
dc.publisherMdpi
dc.relation.ispartofBiomolecules
dc.sourceWeb of Science
dc.subjectmyocardial infarction
dc.subjectcardiovascular disease
dc.subjectmesenchymal stem cells
dc.subjectexosomes
dc.subjectextracellular vesicles
dc.subjectcardioprotection
dc.subjectcardiac regeneration
dc.subjectcell-free therapy
dc.titleNovel Applications of Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Therapeuticsen
dc.typeResenha
dcterms.rightsHolderMdpi
unesp.author.orcid0000-0001-7324-0687[5]

Arquivos

Coleções

Artigos